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Résumé 
Valeur prédictive des anticorps dirigés contre le cytoplasme des neutrophiles 
(ANCA) dans les vasculites des vaisseaux de petit calibre 
But du travail : 
Les vasculites sont des pathologies le plus souvent sévères et parfois létales ; elles 
nécessitent une reconnaissance et un traitement précoces. Il est donc utile de 
pouvoir disposer de marqueurs diagnostiques, et éventuellement de marqueurs qui 
puissent prédire l'activité de la maladie. 
Les « antineutrophil cytoplasm antibodies » (ANCA) constituent une famille d'auto-
anticorps dirigés contre des antigènes du cytoplasme des neutrophiles, cellules clés 
du processus inflammatoire au cours des vasculites. De nombreuses études ont 
tenté de préciser l'utilité des ANCA dans le diagnostic et le suivi des vasculites avec 
des résultats contradictoires. Le but de ce travail a été de passer en revue l'évolution 
clinique des patients suivis dans notre service pour une vasculite à ANCA et évaluer 
la valeur prédictive des ANCA comme marqueur de récidive. 
Méthode: 
Les dossiers médicaux de 36 patients, suivis à notre consultation ambulatoire 
d'immunologie et allergie du CHUV pour une vasculite à ANCA entre janvier 1990 et 
décembre 2001, ont été analysés de manière rétrospective afin d'établir une base de 
données. Les données démographiques, le type de vasculite (granulomatose de 
Wegener ou polyangéite microscopique) et ses caractéristiques (organes touchés), 
les traitements reçus, les dosages des ANCA (par immunofluorescence et par ELISA 
avec détermination des anti-PR3 eVou anti-MPO), et l'évolution clinique 
(récidive/rémission) ont été considérés. 
La valeur pronostique des ANCA dans notre population a été calculée utilisant les 
valeurs prédictives positive et négative, la likelihood et les odds ratios. La valeur 
statistique a été examinée par les tests Chi-square test ou Fisher's exact test (valeur 
significative définie comme p <0.05) à l'aide du programme GraphPad lnstat software 
version 3, San Diego, CA. 
Résultats: 
Vingt-trois patients atteints d'une maladie de Wegener et treize d'une polyangéite 
microscopique ont été suivis pour une durée médiane de cinq ans (entre 1 mois et 16 
ans). La plupart des patients ont été traités avec des corticostéroïdes associés à du 
cyclophosphamide. Une rémission a été obtenue chez 21 patients (91 %) atteints 
d'une maladie de Wegener, mais 74% ont présenté par la suite une récidive. Tous 
les patients atteints d'une polyangéite microscopique sont entrés en rémission et 
33% ont par la suite récidivé. Une élévation persistante (définie comme supérieure à 
6 mois) des ANCA ne s'est pas révélée associée à un risque statistiquement 
significatif de récidive (JJ=0.14). En revanche, une élévation soudaine du taux des 
ANCA s'est démontrée prédictive d'une récidive (table 3). 
Conclusion : 
Durant le suivi de certaines vasculites, comme la granulomatose de Wegener et la 
polyangéite microscopique, une élévation des ANCA doit faire redouter une 
exacerbation de la maladie et, par conséquent, justifie une surveillance accrue. 
Predictive Value of Antineutrophil Cytoplasmic 
Antibodies in Small-Vessel Vasculitis 
FLORIANA LURATI-RUIZ and FRANÇOIS SPERTINI 
ABSTRACT. Objective. The predictive value of antineutrophil cytoplasmic antibodies (ANCA) as markers of clin-
ical activity of small vessel vasculitis is controversial. We reviewed the outcome of patients with 
ANCA-associated vasculitis from a single center and evaluated the predictive value of ANCA as 
markers of relapse. 
Methods. The medical history of all consecutive patients withANCA-associated vasculitis followed 
at our outpatient clinic was retrospectively reviewed. ANCA were monitored by immunofluores-
cence and by ELISA (antiproteinase 3 and antimyeloperoxidase). 
Results.1\venty-three patients with Wegener's granulomatosis and 13 with microscopie polyangiitis 
were followed for a median period of 5 years (1 mo-16 yrs). Most patients were treated with com-
bined corticosteroids and cyclophosphamide. In the Wegener's granulomatosis group, remission was 
obtained in 21 of 23 patients (91 %), within 4-48 weeks (median 7.5); relapses occurred in 74%. In 
the microscopie polyangiitis group, remission was obtained in ail patients within 3-38 weeks (medi-
an 8); relapses occurred in 33%. In contrast to persistently (> 6 mo) elevated ANCA titers, which 
were not significantly associated with disease relapse, the predictive value of an acute rise in ANCA 
titers was strongly associated with the magnitude of the increase. 
Co11clusio11. Our study demonstrates the weak predictive value of persistently elevated ANCA titers, 
in contrast to acute rises in ANCA titers. Although an acute rise in ANCA titers may help in a deci-
sion whether to introduce immunosuppressive therapy, the final decision has to be based on both 
clinical and laboratory markers. (J Rheumatol 2005;32:2167-72) 
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Antineutrophil cytoplasmic antibodies (ANCA) are autoan-
tibodies directed against the cytoplasmic granules of neu-
trophils and monocytes. ANCA were first reported in 1982 
in 8 patients with segmental necrotizing glomerulonephri-
tis 1• They are essential markers and contribute to classifica-
tion of small vessel vasculitis, such as Wegener's granulo-
matosis (WG), microscopie polyangiitis (MPA), and renal-
limited vasculitis, which together are categorized as ANCA-
associated systemic vasculitides (AA v)2-6• The Chape! Hill 
criteria7, which do not yet take into account ANCA positiv-
ity and antigen specificity, are currently under revision. In 
patients with WG, ANCA dis play a diffuse cytoplasmic pat-
tern (cANCA) when detected by indirect immunofluores-
cence (IF) on ethanol-fixed neutrophils, and are usually 
directed against proteinase 3 (PR3)8•9• The use of indirect IF 
or ELISA alone resulted in unsatisfactory diagnostic speci-
ficity; however, the combination of IF with PR3- and 
myeloperoxidase (MPO) ELISA showed a 99% specificity 
for diagnosis of AAV2•6• ANCA sensitivity in WG has been 
reported to be in the range of 34%-92%3• Despite the great 
variability of the studied populations, c-ANCA/anti-PR3 
specificity (proportion of patients without WG who have a 
negative test result) is in the range of 80%-100%3. In MPA 
patients, ANCA display a perinuclear pattern (pANCA) and 
usually target MP09. The proportion of MPA with positive 
pANCA/MPO is reported to be in the range of 40%-80%4• 
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Immunosuppressive therapy for AAV has considerably 
reduced mortality, but morbidity remains high because of 
frequent relapse. In view of the high relapse rate of WG 
despite optimal immunosuppressive therapy, early detection 
and prediction of relapse is crucial. The clinical utility of 
serial measurements of ANCA has been examined by sever-
al groups, but their value in monitoring disease activity 
remains controversial. The sensitivity of arise in ANCA for 
the diagnosis of relapse appears to be as low as 24% and as 
high as 100%5,l0-21 • Different definitions of disease activity, 
study designs, methods, and timing of ANCA testing may 
explain in part the high variability of results. 
In this retrospective study, we reviewed response to ther-
apy and relapse rate in our series of patients with WG and 
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MPA, and evaluated the value of serial ANCA titer meas-
urement in predicting relapse. 
MATERIALS AND METHODS 
Patients. The medical history of 36 consecutive patients (21 men, 15 
women) with WG or MPA was reviewed retrospectively. Median age was 
56 years old (range 17-82). Biopsy-proven vasculitis was demonstrated in 
32 cases. In 4 patients wîth a clînical presentation and Iaboratory findings 
that strongly suggested diagnosis of vasculitis, treatment was started with-
out invasive biopsy procedures. Patients were classified in 2 groups accord-
ing to the Chapel Hill crîteria7: 23 were diagnosed as WG and 13 as MPA. 
Ali patients were followed for a median period of 5 years (range l mo to 
16 yrs). 
Vasculitis remission and relapse. Patients were considered to be in remis-
sion when the following criteria were fulfilled20: (1) return to good gener-
al condition; (2) absence of manifestations of AAV; (3) normal erythrocyte 
sedimentatîon rate (ESR) and/or C-reactive protein (CRP). Relapse was 
defined as the reappearance of AAV related symptoms and worsening of 
general condition, justifying treatment adjustment. 
ANCA assays. ANCA were screened by IF (Nova Lite™ ANCA, Inova 
Diagnostics, San Diego, CA, USA) then titrated by ELISA for anti-MPO 
and anti-PR3 antibodies (Quanta Lite™, Inova Diagnostics). An acute rise 
in ANCA titer (as measured by ELISA) was defined as an increase in the 
most recent sample tîter of 2: 1.2-, 1.5-, 2-, 3-, or 4-fold, resulting in a liter 
2: 20 U 19. An acute rise in ANCA titer was considered to indicate clinical 
relapse when occurring within 6 months of the relapse or at the time of the 
event. Persistently positive ANCA tîters were defined as steadily elevated 
titers 2: 20 U for more than 6 months5•19.2 1. Persistently positive ANCA 
titers were considered to indicate clînical relapse when relapse occurred 
during the period of positive ANCA titers. 
Statistica/ methods. The prognostic value of persistently elevated ANCA 
titers or acute rises in ANCA at various Ievels was assessed by measuring 
positive and negative predictive values, and Iîkelîhood and odds ratios. 
Statistical significance was examined by the chi-square test or Fisher's 
exact test. P values were judged significant when they were 0.05 or less. 
Statistical analysis was done using GraphPad Instat software version 3 
(Instat, San Diego, CA, USA). 
RESULTS 
Patient characteristics. Among the 23 patients with WG, 
96% (22/23) were positive for cANCA, 4% (1/23) for 
pANCA, 78% (18/23) for anti-PR3 antibodies, and 4% 
(1/23) for anti-MPO antibodies. Among the 13 patients with 
MPA, 85% (11/13) were positive for pANCA, 15% (2/13) 
for cANCA, 61 % (8/13) for anti-MPO antibodies, and 7 .7% 
(1113) for anti-PR3 antibodies. 
At diagnosis, renal, pulmonary, and joint manifestations 
were the most frequent features in both groups, with associ-
ated ear, nose, and throat manifestations in the WG group 
and neurological manifestations in the MPA group. In a 
comparison using chi-square test, the profile of target organ 
manifestations in both diseases differed significantly (Table 
1; chi-square test, p = 0.02). At diagnosis, median serum 
levels of CRP and ESR were 104 mg/l (25%-75% percentile 
range: 25-170) and 90 mm/h (25%-75% percentile range: 
65-115) in the WG group, 59 mg/l (25%-75% percentile 
range: 53-125) and 84 mm/h (25%-75% percentile range: 
58-100) in the MPA group. 
Therapy. As remission induction therapy, 21 patients (58%) 
Table 1. Patient characteristics at diagnosis. 
Wegener's Granulomatosis, Microscopie Polyangiitis, 
n=23 n=l3 
Male/female ratio, n (%) 15/8 (65) 
Age, median, range, yrs 56 (17-82) 
Organ system involvement, n (%) 
Kidney 18 (78) 
Lung 14 (61) 
Bar, nose, throat 14 (61) 
Joints 12 (52) 
Skin l (4) 
Eyes 5 (22) 
Nervous system 6 (26) 
617 (46) 
63 (46-82) 
8 (62) 
4 (31) 
0 (0) 
4 (31) 
3 (23) 
2 (15) 
6 (46) 
were treated with intravenous (IV) corticosteroids (methyl-
prednisolone 500 mg/day for 3 days) and all received 
tapered oral prednisone (starting with 1 mg/kg). Thirty-two 
patients (89%) received cyclophosphamide: 6/36 (17%) 
oral22, 27/36 (75%) IV regimen23 (a single patient received 
cyclophosphamide first orally, then by IV). Two patients 
(one with WG limited to the oropharyngeal area and one 
with MPA) were treated with oral corticosteroids and 
methotrexate. Another patient with WG limited to upper res-
piratory airway and joint involvement was treated with oral 
corticosteroids only. A fourth patient, diagnosed as MPA 
with peripheral nervous system involvement, was treated 
with oral corticosteroids and azathioprine. Three patients 
required short term and 3 others longterm dialysis, of whom 
2 subsequently underwent kidney transplantation. 
Remission. According to criteria defined in Materials and 
Methods, remission was obtained in 21/23 patients (91 %) in 
the WG group in 4-48 weeks (median 7.5). In the MPA 
group, remission occurred in all patients within 3-38 weeks 
(median 8). 
Relapse. To keep our analysis of relapse rate clinically rele-
vant, only patients followed for a minimum of 11 months 
were considered (19 WG, 9 MPA). Over a mean followup of 
5 years, a total of 21 relapses occurred in 14 of 19 patients 
(74%) with WG [one relapse in 7 patients (37%), 2 relapses 
in 6 patients (31%), and 4 in one patient]. Time to first 
relapse was 15 months (range 2-32 mo). In the MPA group, 
a total of 4 relapses occurred in 3 of 9 patients (33%; one 
relapse in 2 patients, and 2 in one patient). Time to first 
relapse was 36 months (range 32-41). Clinical characteris-
tics of patients at the time of first relapse are shown in Table 
2. Relapse incidence in the WG group was significantly 
higher than in the MPA group (clinical presentations with or 
without relapse in WG vs MPA; Fisher's exact test, p = 
0 .039). Relapses were initially treated in 6 of the 17 patients 
(35%) with IV corticosteroids (methylprednisolone 500 
mg/day for 3 days) and all 17 patients received tapered oral 
prednisone (starting with 1 mg/kg) for at least 6 months. 
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Table 2. Clinicat manifestations at first relapse. 
Wegener's Granulomatosis, Microscopie Polyangiitis, 
n = 14 n = 3 
Male,n (%) 11 (79) 
Organ system involvement, n (%) 
Kidney 4 (29) 
Lung 7 (50) 
Ear, nose, throat 4 (29) 
Joints 4 (29) 
Skin 0 (0) 
Eyes 1 (7) 
Nervous system 3 (21) 
1 (33) 
1 (33) 
1 (33) 
0 (0) 
1 (33) 
0 (0) 
0 (0) 
3 (100) 
Twelve patients (71 %) received cyclophosphamide (oral 2, 
IV 10), 2 methotrexate, one azathioprine, and one mycophe-
nolate mofetil as maintenance therapy for one year. 
Immunosuppressive therapy for relapse was introduced, not 
based on ANCA titers, but based on the level of clinical dis-
ease activity. Among the 17 patients with first relapse, 5 
were still under induction phase therapy when relapse 
occurred. Three of the 7 patients (43%) who experienced a 
second relapse were still receiving immunosuppressive ther-
apy for their first relapse. 
Adverse events. Only moderate and severe treatment-related 
adverse events (AE) were considered. Twenty-two AE, 
dominated by infectious complications (73%), were report-
ed in 12 of 33 (36%) patients treated with oral or IV 
cyclophosphamide. Out of 16 infectious events: 5 pneumo-
nias (31 %; one complicated by septicemia), 3 urinary infec-
tions (19%; one complicated by septicemia), 2 gastrointesti-
nal infections (12%; one complicated by septicemia), 2 cuta-
neous infections (12%), and one hemodialysis catheter 
infection with septicemia. In 3 other cases, septicemia was 
ofunknown origin. The other AE potentially related to treat-
ment included a single episode each of uric ureteral lithiasis, 
hemorrhagic cystitis, and myelodysplastic syndrome. The 
myelodysplastic syndrome occurred 16 years after initial 
diagnosis in a patient with WG who had had 5 relapses. Six 
patients died (17%), one from infectious complications of 
the immunosuppressive therapy, the others from unrelated 
causes. 
Acute rise in ANCA titers versus persistent/y positive ANCA 
titers. As defined, 28 patients with WG or MPA with a min-
imum followup of 11 months were included in the analysis. 
We observed 37 episodes of 1.2-fold acute rises in ANCA 
titers, 16 of them (in 12 patients) being associated with 
relapse. For a 1.5-fold increase, 32 episodes occurred in 12 
patients, 15 associated with relapse. For a 2-fold increase, 
21 episodes occurred in 10 patients, 12 associated with 
relapse. For a 3-fold increase, 10 episodes occurred in 7 
patients, 7 associated with relapse; and for a 4-fold increase, 
7 episodes occurred in 6 patients, 6 associated with relapse. 
Ali acute rises in ANCA titers occurred within 6 months of 
relapse or at the time of relapse. At any fold-increase, acute 
ANCA rises were significantly associated to relapse (Table 
3, Fisher's exact test). However, the specificity and positive 
predictive value of the ANCA rise grew in parallel to the 
magnitude of the rise. Specificity and positive predictive 
value culminated at 70% and 95%, respectively, for a 3-fold 
increase in ANCA titer, and at 86% and 98% for a 4-fold 
increase. Likelihood was as high as 5.6 and 14.5, respec-
tively. As expected in these conditions, the sensitivity of the 
test was marginal, 29% and 25%, respectively. At lower 
fold-increase (1.2- to 2-fold), sensitivity improved, but to 
the detriment of positive predictive value and likelihood, 
which were weak (1.8 to 3.2). With regard to persistently 
positive ANCA titers, relapses occurred in 10 of 24 
episodes, allowing calculation of sensitivity and specificity 
of the test of 42% and 78%, respectively; positive and neg-
ative predictive value of 59% and 64%, respectively; and a 
likelihood and odds ratio of 1.9 and 2.6, respectively. In 
these conditions, persistently positive ANCA titers were not 
significantly associated with relapse (p = 0.14, Fisher's 
exact test). 
DISCUSSION 
The diagnosis and classification of patients with vasculitis is 
based on clinical and histopathological criteria, and may 
therefore be susceptible to serious limitations as long as 
ANCA types are not taken into account. ANCA might cer-
tainly add value to diagnosis criteria specificity, and could 
logically be used in combination with clinical and 
histopathological findings for establishing a specific diag-
nosis, as currently considered in the revised Chapel Hill cri-
teria 7 • With regard to the spectrum of clinical expression, 
prevalence of renal involvement may vary during the course 
of disease, but in our study globally it did not differ between 
anti-PR3 and anti-MPO-positive patients with vasculitis, 
and prevalence reported in the literature is in the range of 
75% to 90% of cases24.Although they considerably overlap, 
we observed a profile of clinical characteristics that differ-
entiated the anti-PR3 from the anti-MPO-associated vas-
culitis clearly (chi-square test, p = 0.02). Upper respiratory 
tract involvement was largely more frequently reported in 
our anti-PR3 than anti-MPO-positive patients, in agreement 
with several other reports25. This was the case as well for 
pulmonary and joint involvement in the WG group, 
although others have reported comparable frequencies26 . 
Skin and nervous system involvement was found, in con-
trast, more frequently in MPA than in WG patients. 
Concerning demographic characteristics, we found a pre-
ponderance of male patients with anti-PR3 (M/F ratio 1.3 to 
1.9) and of female patients with anti-MPO-associated vas-
culitis (M/F ratio 0.3 to 0.8) as described24•25. AAV primari-
ly affects older patients, although age range can also include 
pediatric patients. In our study, we found, like others, that 
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Table 3. Statistical analysis of ANCA titers, classified as acute rise or persistent elevation. 
Sensitivity, Specificity, 
ANCA Titer % 95% CI % 95% CI 
Acute rise, fold-increase 
xl.2 67 45-84 64 50-76 
xl.5 63 41-82 71 57-82 
x2.0 50 29-71 84 73-93 
x3.0 29 13-51 95 86-99 
x4.0 25 10-47 98 91-99 
Persistent 
elevation 42 22-63 78 60-90 
PPV: positive predictive value; NPV: negative predictive value. 
patients with anti-MPO antibodies were older than those with 
anti-PR3-associated vasculitis24.25. However, as a general 
caveat, we emphasize the retrospective design of our study, 
the obvious absence of randomization of the study, and poten-
tial lack of comparability between the 2 disease categories. 
Frequency of relapse largely depends on the definition, 
treatment regimen, and duration of followup. Relapse usual-
ly occurs when immunosuppressive treatment dose is 
reduced or interrupted, usually within the first 2 years after 
diagnosis6. Most reports of patients with AAV show a 
roughly 2-fold increase in relapse rate in patients with 
WG22·27 as compared to patients with MPA or renal-limited 
vasculitis28 ·29 . In our study, we confirmed this significant 
trend (relapse rate 74% vs 33%; p = 0.039). Since most 
patients were not under immunosuppressive maintenance 
therapy at the time of their first and second relapse, relapse 
rate was weakly influenced by concomitant therapy. Our 
data, however, strongly support the administration of 3-
week-interval pulsed cyclophosphamide in patients with 
WG and the current practice recommendation of immuno-
suppressive consolidation (with azathioprine, for instance) 
after this induction phase with cyclophosphamide30. 
Our study aimed to examine the prognostic potential of 
an acute rise in ANCA titer, versus a persistently positive 
level of ANCA. Interestingly, when acute rise in ANCA titer 
was stratified in fold-increases to the most recent ANCA 
titer and related to relapse rate, 3- or 4-fold increases were 
strongly predictive of a clinical relapse (Table 3). However, 
sensitivity was low and false-negative rate was particularly 
high (71 % and 75%, respectively). In contrast, the positive 
predictive value and likelihood of a 1.2- to 2-fold increase in 
ANCA titer was rather weak. This strongly suggests that a 
marked acute rise in ANCA titer lends support to prescrib-
ing immunosuppressive therapy. However, in view of the 
high false-negative rate of ANCA, careful monitoring of 
clinical expression is mandatory prior to making a decision 
to treat. As reported by others, persistently positive ANCA 
titers as a predictive factor did not reach a level of signifi-
cance in our study. 
This observation is reminiscent of multiple attempts to 
PPV, NPV, p, 
% 95% CI % 95% CI Likelihood Fisher's test 
43 27-61 82 68-92 1.84 0.015 
47 29-65 82 69-91 2.13 0.007 
57 34-78 80 68-89 3.22 0.002 
70 35-93 76 65-86 5.64 0.006 
86 42-100 76 65-85 14.5 0.002 
59 33-82 64 47-79 1.91 0.14 
correlate various other autoimmune markers with prediction 
of disease activity or of disease-specific organ failure. This 
was the case for anti-dsDNA and more recently for antinu-
cleosome antibodies; results have often been controversial 
and vary widely from one study to another31-33 . In most 
cases, arise in measures such as anti-dsDNA antibodies is 
observed more often at the time of disease activation rather 
than in advance of it32. This, however, does not exclude a 
role for autoantibodies as markers of a potential association 
with disease-specific organ failure or disease activity, such 
as anti-dsDNA with lupus nephritis or antinucleosome anti-
bodies with SLE activity34. With respect to ANCA, the asso-
ciation with clinical relapse as determined by IF or 
expressed as anti-PR3 or anti-MPO antibodies varies wide-
ly, from strong (more than 75%5,IO,ll,14,18,21,35,36), to mod-
erately high, to weaker (25%-75%12·13·19-21 ·37), as recently 
reviewed38·39 . 
The usefulness of ANCA monitoring in WG was first 
studied by Tervaert, et al, who found titers correlated close-
ly with disease activity and predicted ail 17 relapses in a 
prospective study40. In a subsequent study in WG patients, 
the same authors were able to prevent relapses by initiating 
treatment on the basis of the ANCA rise14. Most other suc-
cessive studies were much less conclusive, not only in pre-
dicting relapses in WG but also in MPA, Churg-Strauss syn-
drome, and renal-limited vasculitis, based on IF or ELISA. 
The additional measurement of a rise in the IgG3 subclass 
increased positive predictive value of a rise in ANCA from 
71 % to 91 % but, given its low sensitivity, was of little clin-
ical utility 18 . Despite a significant association between ris-
ing ANCA titers and relapse, Hoffmann, et al estimated that 
about one-third of their patients would not relapse during 
the followup period and would thus have been treated 
unnecessarily15 . In these circumstances, aggressive therapy 
with immunosuppressive agents would of course be unac-
ceptable. However, important discriminative potential was 
recently dernonstrated for anti-PR3, since persistent positiv-
ity was associated in these patients with a higher risk of 
relapse after switching to azathioprine as maintenance 
therapy41 . 
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Our study reinforces the weak predictive value of mar-
ginal acute increases in ANCA titers, although the predictive 
value of marked enhancement in titers reached levels of pre-
dictive value that might help in therapeutic decision-mak-
ing. Further, persistently positive ANCA titers did not corre-
late with relapse. 
ANCA determinations should be considered as ancillary 
measures for patient clinical monitoring, and introduction of 
immunosuppressive therapy should reasonably be based on 
clinical and laboratory markers, as well as a patient's previ-
ous clinical course. 
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